{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:08Z","timestamp":1793600828024,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaci.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:57:59Z","timestamp":1776142679000},"page":"421-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-4520","authenticated-orcid":false,"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Bulai","family":"Livideanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jurcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke Oude","family":"Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cerquozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanai","family":"Pongdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Rein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilda","family":"Bidollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsewang","family":"Tashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","article-title":"Mastocytosis","volume":"11","author":"Akin","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaci.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.001_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2026.04.001_bib4","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.3390\/cancers14163942","article-title":"Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience","volume":"14","author":"Ungerstedt","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.34420","article-title":"Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM Patient Survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"van Anrooij","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/cea.70101","article-title":"Patient-reported outcomes and provider perceptions of systemic mastocytosis: results from the PRISM study","volume":"55","author":"Triggiani","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.04.001_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.04.001_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2026.04.001_bib17","series-title":"AYVAKIT\u00ae (avapritinib)","year":"2024"},{"key":"10.1016\/j.jaci.2026.04.001_bib18","series-title":"Summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jaci.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.001_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13023-021-02035-5","article-title":"Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(\u00a9)","volume":"16","author":"Taylor","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13023-023-02661-1","article-title":"Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF(\u00a9)) and determination of a threshold score for moderate symptoms","volume":"18","author":"Shields","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/all.12842","article-title":"Development and validation of the mastocytosis quality of life questionnaire: MC-QoL","volume":"71","author":"Siebenhaar","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/j.jaip.2021.04.059","article-title":"Health-related quality of life and influencing factors in adults with nonadvanced mastocytosis\u2014a cross-sectional study and qualitative approach","volume":"9","author":"Pulfer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.3390\/ijms26125649","article-title":"Indolent mastocytosis and bone health: molecular mechanisms and emerging treatment options","volume":"26","author":"Jankovski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2023-182322","article-title":"Predicting the clinical course of treatment with midostaurin in patients with advanced systemic mastocytosis","volume":"142","author":"L\u00fcbke","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.001_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971040.47281.9b","article-title":"P1036: real-world efficacy and safety of midostaurin-treatment in patients with advanced systemic mastocytosis","volume":"7","author":"L\u00fcbke","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jaci.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.04.001_bib29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-4632.2004.02114.x","article-title":"Piebaldism: an update","volume":"43","author":"Thomas","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2026.04.001_bib30","doi-asserted-by":"crossref","unstructured":"Piarowski CM, Scott JK, Wilson CE, Lara HI, Salcedo E, Han AS, et al. Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition [preprint]. bioRxiv. https:\/\/doi.org\/10.1101\/2025.08.15.670608.","DOI":"10.1101\/2025.08.15.670608"},{"key":"10.1016\/j.jaci.2026.04.001_bib31","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.jaip.2025.05.026","article-title":"Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosis","volume":"13","author":"Castells","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.3748\/wjg.v28.i29.3767","article-title":"Clinical challenge for gastroenterologists-gastrointestinal manifestations of systemic mastocytosis: a comprehensive review","volume":"28","author":"Elvevi","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaci.2026.04.001_bib33","series-title":"Cromolyn sodium. Teasure Island (FL)","author":"Minutello","year":"2026"},{"key":"10.1016\/j.jaci.2026.04.001_bib34","series-title":"American College of Allergy, Asthma and Immunology Annual Meeting","article-title":"Avapritinib improved gastrointestinal symptoms in patients with indolent systemic mastocytosis: registrational double-blind, placebo-controlled PIONEER study","author":"Ogbogu","year":"2023"},{"key":"10.1016\/j.jaci.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2026.04.001_bib36","series-title":"The socio-emotional impact of indolent systemic mastocytosis: insights from the PRISM survey","author":"Hobart","year":"2025"},{"key":"10.1016\/j.jaci.2026.04.001_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/jocn.14676","article-title":"Everyday life and mastocytosis from a patient perspective\u2014a qualitative study","volume":"28","author":"Jensen","year":"2019","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.jaci.2026.04.001_bib39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/mgg3.315","article-title":"Living with a rare disorder: a systematic review of the qualitative literature","volume":"5","author":"von der Lippe","year":"2017","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jaci.2026.04.001_bib40","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jaad.2026.02.025","article-title":"Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: results from the randomized, phase 2, interventional PIONEER study","volume":"94","author":"Siebenhaar","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.001_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117578","article-title":"The number of vertebral fractures in indolent systemic mastocytosis is influenced by presence of the KIT-mutation","volume":"200","author":"Wilke","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.jaci.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jaci.2026.04.001_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2026.101352","article-title":"Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis","volume":"19","author":"Pongdee","year":"2026","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2026.04.001_bib44","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2026.04.001_bib45","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2026.04.001_bib46","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/bloodadvances.2024012756","article-title":"Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM","volume":"8","author":"Lubke","year":"2024","journal-title":"Blood Adv"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:35:03Z","timestamp":1793597703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0091674926002538"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.001","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}